Abstract
Deletions involving chromosome 9 occur in more than 50% of human bladder cancers of all grades and stages. Most involve loss of the whole chromosome or of an entire chromosome arm but some small deletions are found which can be used to define critical regions which may contain tumour suppressor genes. We have localized such a critical region of deletion at 9q34 between the markers D9S149 and D9S66, an interval which contains the Tuberous Sclerosis gene TSC1. Single strand conformation polymorphism (SSCP) and sequence analysis of TSC1 in bladder tumours and cell lines with 9q34 loss of heterozygosity (LOH) has identified five mutations in retained TSC1 alleles. Our results support the hypothesis that TSC1 can act as a bladder tumour suppressor gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- TCC:
-
transitional cell carcinoma
- LOH:
-
loss of heterozygosity
- SSCP:
-
single strand conformation polymorphism
- TSC:
-
tuberous sclerosis complex
References
Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP . 1998 Adv. Cancer Res. 72: 141–196.
Bjornsson J, Short MP, Kwiatkowski DJ and Henske EP . 1996 Am. J. Pathol. 149: 1201–1208.
Cairns P, Proctor AJ and Knowles MA . 1991 Oncogene 6: 2305–2309.
Cairns P, Tokino K, Eby Y and Sidransky D . 1994 Cancer Res. 54: 1422–1424.
Carbonara C, Longa L, Grosso E, Borrone C, Garre MG, Brisigotti M and Migone N . 1994 Human Mol. Genetics 3: 1829–1832.
Devlin J, Keen AJ and Knowles MA . 1994 Oncogene 9: 2757–2760.
Habuchi T, Devlin J, Elder PA and Knowles MA . 1995 Oncogene 11: 1671–1674.
Habuchi T, Yoshida O and Knowles MA . 1997 Human Mol. Genetics 6: 913–919.
Henry KW, Yuan X, Koszewski NJ, Onda H, Kwiatkowski DJ and Noonan DJ . 1998 J. Biol. Chem. 273: 20535–20539.
Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT and Kwiatkowski DJ . 1996 Am. J. Hum. Genet. 59: 400–406.
Hornigold N, van Slegtenhorst M, Nahmias J, Ekong R, Rousseaux S, Hermans C, Halley D, Povey S and Wolfe J . 1997 Genomics 41: 385–389.
Ishibashi Y, Watanabe R, Nogita T, Takahashi T, Onodera K and Kimura G . 1991 Ann. NY Acad. Sci. 615: 228–242.
Jones AC, Daniells CE, Snell RG, Tachataki M, Idziaszczyk SA, Krawczak M, Sampson JR and Cheadle JP . 1997 Human Mol. Genet 6: 2155–2161.
Keen AJ and Knowles MA . 1994 Oncogene 9: 2083–2088.
Knowles MA . 1998 Cancer Surv. 31: 49–76.
Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE and Cordon-Cardo C . 1994 Cancer Res. 54: 2848–2851.
Pajak L, Jin F, Xiao GH, Soonpaa MH, Field LJ and Yeung RS . 1997 Am. J. Physiol. 273: H1619–H1627.
Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C and Bernstein J . 1998 Am. J. Surg. Pathol. 22: 180–187.
Povey S, Armour J, Farndon P, Haines JL, Knowles M, Olopade F, Pilz A, White JA and Kwiatkowski DJ . 1994 Ann. Hum. Genet. 58: 177–250.
Scappaticci S, Cerimele D, Tondi M, Vivarelli R, Fois A and Fraccaro M . 1988 Hum. Genet. 79: 151–156.
Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC and Godwin AK . 1995 Cancer Res. 55: 2150–2157.
Simoneau AR, Spruck III CH, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai Y, Dean M, Steven K, Horn T and Jones PA . 1996 Cancer Res. 56: 5039–5043.
Soucek T, Pusch O, Wienecke R, DeClue JE and Hengstschlager M . 1997 J. Biol. Chem. 272: 29301–29308.
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ et al.1997 Science 277: 805–808.
van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D and van der Sluijs P . 1998 Hum. Mol. Genet. 7: 1053–1057.
Wolfe J, Jeremiah S, Young J, Burley MW, Stewart H, McCulley M, Grant C, Naz K and Povey S . 1997 Ann. Hum. Genet. 61: 401–409.
Young JM, Burley MW, Jeremiah SJ, Jeganathan D, Ekong R, Osborne JP and Povey S . 1998 Ann. Hum. Genet. in press.
Acknowledgements
The authors thank Hani Gabra for providing DNA samples from ovarian tumours and Sue Povey, Jonathan Wolfe and Janet Young for their assistance both with materials and with helpful discussions. This work was supported by the Imperial Cancer Research Fund and Marie Curie Cancer Care.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hornigold, N., Devlin, J., Davies, A. et al. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18, 2657–2661 (1999). https://doi.org/10.1038/sj.onc.1202854
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202854
Keywords
This article is cited by
-
Genetic profiling as a clinical tool in advanced parathyroid carcinoma
Journal of Cancer Research and Clinical Oncology (2019)
-
Mapping of the chromosomal amplification 1p21-22 in bladder cancer
BMC Research Notes (2014)
-
Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance
Virchows Archiv (2013)
-
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
Nature Genetics (2013)
-
TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity
Oncogene (2010)